Print

ACCESS TO COVID-19 TOOLS (ACT) ACCELERATOR” - IGBA is Joining Forces on Global Collaboration to Overcome COVID-19 (24 April 2020)

IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, today endorses the commitment and call to action by an initial group of global health actors, private sector partners and other stakeholders, to launch an unprecedented global and time-limited collaboration to accelerate the development, production and equitable global access to new COVID-19 essential health technologies.

Print

COVID-19: IGBA calls for urgent priority designation for medicines at custom controls and for cargo and freight (6 April 2020)

The International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, today requests urgent action by all governments to designate all medicines as PRIORITY ESSENTIAL PRODUCTS, including all critical goods needed to manufacture them, so as to ensure that patients around the globe can continue to access the medicines they need during the COVID-19 pandemic.

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

C/O DYN SA
Rue de Cornavin 11
1201 Geneva, Switzerland

Telephone: +32 (0)2 5346607 (S. Kox)
E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or  
Secretary General –   This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site